Y Intercept Hong Kong Ltd Invests $510,000 in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Y Intercept Hong Kong Ltd acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 14,147 shares of the medical device company's stock, valued at approximately $510,000.

Other institutional investors have also recently bought and sold shares of the company. Brooklyn Investment Group acquired a new stake in shares of Tandem Diabetes Care in the third quarter valued at $28,000. Assetmark Inc. bought a new stake in shares of Tandem Diabetes Care during the third quarter valued at approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Tandem Diabetes Care by 4.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company's stock valued at $664,000 after purchasing an additional 704 shares in the last quarter. Hanseatic Management Services Inc. raised its position in Tandem Diabetes Care by 5.4% in the 3rd quarter. Hanseatic Management Services Inc. now owns 13,941 shares of the medical device company's stock worth $591,000 after purchasing an additional 710 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its holdings in Tandem Diabetes Care by 14.0% during the 3rd quarter. Coldstream Capital Management Inc. now owns 6,212 shares of the medical device company's stock worth $263,000 after buying an additional 762 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Robert W. Baird lowered their target price on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research note on Thursday, February 27th. Barclays dropped their price objective on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Canaccord Genuity Group restated a "buy" rating and set a $63.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $35.00 to $24.00 in a research report on Tuesday. Finally, Wells Fargo & Company restated an "equal weight" rating and issued a $22.00 price objective (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $45.38.

Remove Ads

Tandem Diabetes Care Stock Down 1.9 %

Shares of NASDAQ:TNDM traded down $0.38 during trading on Wednesday, hitting $19.11. 2,364,627 shares of the company's stock traded hands, compared to its average volume of 1,500,518. The company has a 50-day moving average price of $33.92 and a 200-day moving average price of $35.86. Tandem Diabetes Care, Inc. has a 52 week low of $18.77 and a 52 week high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -9.90 and a beta of 1.32.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.